Medicare AdvantageCoverageMedium impact
MA08.134e, Trilaciclib (Cosela™)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Jun 11, 2025
We identified it
Jun 19, 2026
Summary
The Medicare Advantage policy for Trilaciclib (Cosela™) has been reissued and updated. This affects coverage and billing for this oncology drug used to reduce chemotherapy-induced bone marrow suppression.
Action Required
By June 11, 2025: Review updated Trilaciclib (Cosela™) policy MA08.134e for Medicare Advantage plans. Billing team should verify current prior authorization requirements, coverage criteria, and documentation needs for this oncology medication. Update billing procedures and inform oncology providers of any changes to ensure compliant claims submission.